Premium
Uptake of novel oral anticoagulants in Australia
Author(s) -
Pratt Nicole L,
Ramsay Emmae N,
Caughey Gillian E,
Shakib Sepehr,
Roughead Elizabeth E
Publication year - 2016
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja15.01000
Subject(s) - medicine , business , geography
linical trials have shown that novel oral anticoagulants C (NOACs) are as efficacious as warfarin in reducing the riskof stroke in patients with atrial fibrillation. However, concerns regarding efficacy and safety in real-world populations remain, particularly in patients aged 75 years and older and those with comorbid conditions. Three NOACs — dabigatran, rivaroxaban and apixaban— were listed by the Pharmaceutical Benefits Scheme in 2013, but there is little information about their uptake in clinical practice in Australia.